Navigation Links
Sirnaomics Seals a Second Partnership Deal with a Chinese Pharmaceutical Company for Developing siRNA Therapeutics
Date:6/23/2011

GAITHERSBURG, Md., June 23, 2011 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has signed a partnership agreement with Guangdong Zhongsheng Pharmaceutical Co. Ltd., a Chinese pharmaceutical company trading on the Shenzhen Stock Exchange (SZSE: 002317). The partnership will focus on development of small interfering RNA (siRNA) therapeutics to treat diabetic retinopathy and age-related macular degeneration.  This is the second partnership deal for Sirnaomics with a publicly traded Chinese pharmaceutical company – following the one signed six months ago with Guangzhou Xiangxue Pharmaceutical Co. Ltd. (SZSE: 300147) (PRNewswire news release on December 2nd, 2010).

Sirnaomics is a leading biopharmaceutical company in the discovery and development of RNA interference (RNAi) therapeutics.  With its proprietary technologies using multi-targeted siRNA cocktail design and nanoparticle-enhanced therapeutic delivery, Sirnaomics has developed an enriched pipeline of siRNA therapeutic product candidates, including STP705 for scarless wound healing, STP601 for ocular diseases, STP702 for respiratory influenza viral infection, STP801 for lung cancer amongst other programs.  While maintaining its IP portfolio with global rights, Sirnaomics has authorized its Chinese affiliate Suzhou Sirnaomics Pharmaceutical Co. Ltd. to hold and further develop the company's intellectual property rights in China.  

The current partnership will pursue clinical development and commercialization of Sirnaomics' therapeutic product candidate (STP601), for treatment of ocular neovascularization conditions, in the Greater China and Southeast Asia markets. Sirnaomics previously completed a pre-IND meeting with the US FDA and determined ongoing IND enabling studies for the STP601 program. Guangdong Zhongsheng Pharmaceutical Co. Ltd. is committing RMB 63 million yuan (US$9.75 million), including upfront and milestone payments to the partnership in addition to a royalty sharing and market territory sharing arrangement with Sirnaomics. This partnership signifies another major step in the siRNA therapeutic field specifically in the Greater China region. The two partnerships Sirnaomics has established not only enable the company to accelerate its development of siRNA therapeutic programs in China and Asia, but should also encourage further investments in the field of RNAi technologies in China and throughout the world.

"The partnerships with two public pharmaceutical companies in China mark a major milestone for Sirnaomics' endeavour on development and commercialization of siRNA therapeutics," said President and CEO of the company, Dr. Patrick Y. Lu. "While the Chinese pharmaceutical industry embraces our novel and innovative therapeutic programs, we receive financial support and expanded capacity as well to develop and commercialize our pharmaceutical products in China." Dr. Lu further commented, "We are excited to be able to pursue two of our siRNA therapeutic products in clinical studies in China."

"Sirnaomics' success in building partnerships with publicly traded pharmaceutical companies in China reflects both a willingness to embrace advanced technologies and the financial strength of those Chinese pharmaceutical companies," said Dr. David Evans, Executive Vice President for R&D of Sirnaomics. "This partnership will help accelerate our effort to develop the siRNA therapeutic programs in the US and other markets." Dr. Evans also indicated that the experience in preclinical safety assessment, CMC/Process Development, formulation and assay development, as well as the clinical trial designs gained during the studies in China will provide strong support to the company's ongoing effort for product development in the US.

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established in 2007 by a group of leading scientists in the field of RNAi technology, the company is pursuing the mission of advancing RNAi technology with novel multi-targeted therapeutic development. In 2008, the company established its subsidiary in Suzhou, China to expand its R&D capacity and potential market. Members of the senior management team bring over 80 years of combined experience in the biopharmaceutical, financial and business management industries. Supported with funding from angel investors, corporate partnerships, government grants and China-Singapore VC, Sirnaomics has developed a strong portfolio of intellectual properties with an enriched product pipeline. The therapeutic areas of interest include regenerative medicine (wound healing), diabetic therapeutics, antiviral therapies, oncology therapeutics, and others.

CONTACT:
George Ji
VP for Corporate Development
Sirnaomics, Inc.
Tel: +1-301-740-1730
Fax: +1-301-740-1731
Info-office@sirnaomics.com
www.sirnaomics.com


'/>"/>
SOURCE Sirnaomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Lung Association Celebrates 101st Annual Christmas Seals Campaign
2. Applied Seals North America Extends Global Network With Addition of Distributor in Europe
3. Applied Seals North America Bolsters Engineering and Applications Services in Silicon Valley With Addition of Design Engineer
4. Higher Education Foundation in Brazil Seals Its Continued Relationship with Thomson Reuters for Academic Healthcare Content
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):